Trade GW Pharmaceuticals
GW Pharmaceuticals is a British pharmaceutical company known for its multiple sclerosis treatment products (brand name, Sativex) which was the first natural cannabis plant derivative to obtain market approval in any country. The U.S. Food and Drug Administration approved epilepsy treatment in 2018, another cannabis-based product, Epidiolex. GW Pharmaceuticalwas founded in 1998 by doctors Jeffrey Guy and Brian Whittle. In that year, they obtained an agricultural licence from the British Home Office and the United Kingdom Department of Public Health, allowing the company to grow, possess and supply cannabis to conduct scientific research on the medicinal uses of the plant. Later that year, JW Pharmaceuticals entered into a contract with Hortafarm B.V., a cannabis research and development company based in Amsterdam. The company was founded by two horticultural experts from California, Robert Connell Clark and David Paul Watson, and specialized strains of cannabis have grown and evolved with the permission of the Dutch government. In 2001, GW Pharmaceuticals listed on AIM, the junior market of the London Stock Exchange. In May 2013, the company became a double on NASDAQ and AIM. Nabiximols (brand name Sativex) is a plant drug that is a cannabis extract, administered as a oral spray; it was approved in the UK in 2010 as a treatment for patients with multiple sclerosis (MS) to relieve neuralgia, cramping, bladder hyperactivity, and other symptoms. nabiximols is made of two unknown hemp strains, and is extracted with ethanol and carbon dioxide. In 2011, GW Pharmaceuticals entered into a partnership With Bayer to distribute Sativex in the UK, its annual production is estimated at 100 tons of medicinal cannabis since 2012.